Patents Assigned to Pfizer
  • N-phenpropylcyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase
    Publication number: 20040106611
    Abstract: The invention relates to compounds of formula (I) for treating for example sexual dysfunction, wherein R1 is optionally substituted C1-6alkyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, hydrogen, C1-6alkoxy, —NR2R3 or —NR4SO2R5; X is the linkage —(CH2)n— or —(CH2)q—O— (wherein Y is attached to the oxygen); wherein one or more hydrogen atoms in linkage X may be replaced independently by C1-4alkoxy; hydroxy; hydroxy(C1-3alkyl); C3-7cycloalkyl; carbocyclyl; heterocyclyl; or by C1-4alkyl optionally substituted by one or more fluoro or phenyl groups; n is 3, 4, 5, 6 or 7; and q is 2, 3, 4, 5 or 6; and Y is phenyl or pyridyl, each of which may be substituted; or two R8 groups on adjacent carbon atoms together with the interconnecting carbon atoms may form a fused optionally substituted 5- or 6-membered carbocyclic or heterocyclyic ring.
    Type: Application
    Filed: October 28, 2003
    Publication date: June 3, 2004
    Applicant: Pfizer Inc
    Inventors: Stephen Challenger, Andrew Simon Cook, Adam Thomas Gillmore, Donald Stuart Middleton, David Cameron Pryde, Alan Stobie
  • Phenyl heterocyclyl ethers
    Publication number: 20040106594
    Abstract: The invention relates to compounds of formula I 1
    Type: Application
    Filed: November 25, 2003
    Publication date: June 3, 2004
    Applicant: Pfizer Inc
    Inventors: Mavis D. Adam, Mark D. Andrews, Geoffrey E. Gymer, David Hepworth, Harry R. Howard, Donald S. Middleton, Alan Stobie
  • Diazabicyclic compounds useful in the treatment of CNS and other disorders
    Publication number: 20040106603
    Abstract: The present invention relates to a compounds of formula I: 1
    Type: Application
    Filed: September 8, 2003
    Publication date: June 3, 2004
    Applicant: Pfizer Inc
    Inventors: Jotham W. Coe, Christopher J. O'Donnell, Brian T. O'Neill, Lawrence A. Vincent
  • Novel process for the preparation of pyrazolopyrimidinones
    Publication number: 20040106796
    Abstract: There is provided a process for the production a compound of general formula I: 1
    Type: Application
    Filed: November 25, 2003
    Publication date: June 3, 2004
    Applicant: Pfizer Inc
    Inventors: Peter James Dunn, Catherine Dunne
  • Process for the preparation of nonracemic syn-1-(4-hydroxy-phenyl)-2-(4-hydroxy-4-phenyl-piperidin-1-yl)-1-propanol compounds
    Patent number: 6743921
    Abstract: The present invention provides a process for the preparation of a nonracemic diastereomer of 1-(4-benzoxy-phenyl)-2-(4-hydroxy-4-phenyl-piperidin-1-yl)-1-propanol by hydrogenation of a corresponding nonracemic 1-(4-benzoxy-phenyl)-2-(4-hydroxy-4-phenyl-piperidin-1-yl)-1-propanone using a catalyst system comprising ruthenium, a nonracemic diphosphine ligand, a bidentate amine ligand selected from amino-thioethers and achiral diamines, and a base.
    Type: Grant
    Filed: January 24, 2002
    Date of Patent: June 1, 2004
    Assignees: DSM Catalytica Pharmaceuticals, Inc., Pfizer, Inc.
    Inventors: Charles E. Tucker, Qiongzhong Jiang
  • Use of PDE V inhibitors for improved fecundity in mammals
    Patent number: 6743799
    Abstract: The invention relates to the use of a cyclic guanosine 3′,5′-monophosphate phosphodiesterase type five (cGMP PDE V) inhibitor for increasing fecundity in a mammal by one or more of (a) promoting the growth of an oocyte, zygote, blastocyst, embryo and/or foetus, (b) increasing the rate or probability of survival of an embryo and/or foetus and (c) increasing the birth weight of a progeny, or for increasing milk productivity.
    Type: Grant
    Filed: August 27, 2002
    Date of Patent: June 1, 2004
    Assignee: Pfizer Inc.
    Inventors: Simon Lempriere Westbrook, Johannes Fridrich Zanzinger
  • 3-Amino-piperadine derivatives and methods of manufacture
    Publication number: 20040102627
    Abstract: This invention relates to 3-amino piperadine derivatives, their intermediates and methods of manufacture.
    Type: Application
    Filed: November 20, 2003
    Publication date: May 27, 2004
    Applicant: Pfizer Inc.
    Inventor: David H.B. Ripin
  • Crystallization method and apparatus using an impinging plate assembly
    Publication number: 20040098839
    Abstract: A crystallization process for generating a pharmaceutical product from solutions of pharmaceutically active compounds or their reactive intermediates employs fluid jet streams containing pharmaceutically active ingredients, appropriate anti-solvents and/or their reactive intermediates capable of producing a pharmaceutical product with desired particle size characteristics upon mixing, chemical reaction, nucleation and precipitation. The jet streams are directed towards an impinging plate, and mixing occurs as the jet streams impinge the plate at a desired area of impact.
    Type: Application
    Filed: November 13, 2003
    Publication date: May 27, 2004
    Applicant: Pfizer Inc.
    Inventors: Steven J. Brenek, David J. Am Ende
  • Pyrimidine carboxamides useful as inhibitors of PDE4 isozymes
    Patent number: 6740655
    Abstract: This invention is directed to compounds of the formula: wherein j is 0 or 1; k is 0 or 1; m is 0 or 1; n is 0 or 1; W is —O—; —S(═O)t—, where t is 0, 1, or 2; or —N(R3)—; where R3 is —H, —(C1-C3) alkyl, —OR12, phenyl, or benzyl; RC and RD have the same meaning as RA and RB, except that at least one of RC and RD must be —H; and the other variables are defined as set forth in the specification. The invention is also directed to pharmaceutical compositions comprising the above compounds and to methods of treating a subject suffering from a disease, disorder or condition mediated by the PDE4 isozyme, the method comprising administering a therapeutically effective amount of a compound as described above.
    Type: Grant
    Filed: July 24, 2002
    Date of Patent: May 25, 2004
    Assignee: Pfizer Inc
    Inventors: Thomas Victor Magee, Anthony Marfat, Robert James Chambers
  • ENANTIOMERS OF 6-[(4-CHLORO-PHENYL)-HYDROXY-(3-METHYL-3H-IMIDAZOL-4-YL)-METHYL]-4-[3-(3-HYDROXY-3-METHYL-BUT-1-YNYL)-PHENYL]-1-METHYL-1H-QUINOLIN-2-ONE AND SALTS THEREOF, USEFUL IN THE TREATMENT OF CANCER
    Patent number: 6740757
    Abstract: This invention relates to the enantiomers of 6-[(4-chloro-phenyl)-hydroxy-(3-methyl-3H-imidazol-4-yl)-methyl]-4-[3-(3-hydroxy-3-methyl-but-1-ynyl)-phenyl]-1-methyl-1H-quinolin-2-one, prodrugs thereof, and pharmaceutically acceptable salts and solvates of said compounds and said prodrugs, that are useful in the treatment of hyperproliferative diseases, such as cancers, in mammals. The invention also relates to processes for the production of enantiomerically pure or optically enriched (+)- or (−)-6-[(4-chloro-phenyl)-hydroxy-(3-methyl-3H-imidazol-4-yl)-methyl]-4-[3-(3-hydroxy-3-methyl-but-1-ynyl)-phenyl]-1-methyl-1H-quinolin-2-one enantiomers from a mixture containing two enantiomers using continuous chromatography.
    Type: Grant
    Filed: August 27, 2002
    Date of Patent: May 25, 2004
    Assignee: Pfizer Inc
    Inventors: R. Mark Guinn, Subramanian Sam Guhan, Karl K Ng, Derek L. Tickner, Marcus Douglas Ewing, Clifford N. Meltz, Bryan Li, Kees Pouwer
  • Suspension method for producing embryoid bodies, compositions and methods related thereto
    Publication number: 20040096967
    Abstract: Suspension methods and compositions for effecting large-scale in vitro differentiation of mammalian embryonic stem cells are provided, as well as methods comprising the subject large-scale in vitro differentiation methods.
    Type: Application
    Filed: October 31, 2003
    Publication date: May 20, 2004
    Applicant: Pfizer Inc
    Inventors: Timothy D. Gryseels, John E. Hambor, Steven J. Hawrylik, Marsh L. Roach
  • Diaryl compounds
    Publication number: 20040097509
    Abstract: The invention relates to compounds of formula I 1
    Type: Application
    Filed: July 31, 2003
    Publication date: May 20, 2004
    Applicant: Pfizer Inc.
    Inventors: Mark David Andrews, David Hepworth, Donald Stuart Middleton
  • Heteroaryl-hexanoic acid amide derivatives as immonomodulatory agents
    Publication number: 20040097554
    Abstract: The present invention relates to compounds of the formula (I) 1
    Type: Application
    Filed: October 16, 2003
    Publication date: May 20, 2004
    Applicant: Pfizer Inc
    Inventors: Matthew F. Brown, Anderson S. Gaweco, Ronald P. Gladue, John C. Kath, Christopher S. Poss
  • Method of treating parasitic infection
    Publication number: 20040097435
    Abstract: When selamectin is administered to a female animal over a period commencing during pregnancy and ending during lactation, endo- and ecto-parasite infestations are either treated or prevented in that animal's offspring, avoiding the problems of treating the offspring directly. This leads to improvements in the compliance of dosing and hence the efficacy of treatment and reduces the number of doses to be administered leading to economic benefits and greater convenience.
    Type: Application
    Filed: November 12, 2003
    Publication date: May 20, 2004
    Applicant: Pfizer Inc
    Inventors: Hafid Abdelaali Benchaoui, Antoinette Beaton Drain Jernigan, Mark Payne-Johnson, Timothy George Rowan
  • Compositions and methods for protecting animals from lentivirus-associated disease such as feline immunodeficiency virus
    Publication number: 20040096460
    Abstract: The present invention is directed to a novel strain of feline immunodeficiency virus, designated herein as FIV-141, and to attenuated forms of the virus produced by mutating specific regions of the viral genome. The virus and mutated forms of the virus may be used to induce the production of antibodies to FIV-141, and in vaccines designed to protect cats from FIV.
    Type: Application
    Filed: November 6, 2003
    Publication date: May 20, 2004
    Applicant: Pfizer Inc
    Inventors: Ruitang Deng, Michael G. Sheppard
  • Mutual prodrug of amlodipine and atorvastatin
    Patent number: 6737430
    Abstract: The present invention relates to a mutual prodrug of amlodipine and atorvastatin, pharmaceutically acceptable acid addition salts thereof, pharmaceutical compositions thereof and the use of said prodrug and its salts in the manufacture of medicaments for the treatment of atherosclerosis, angina pectoris, combined hypertension and hyperlipidaemia and the management of cardiac risk.
    Type: Grant
    Filed: October 31, 2001
    Date of Patent: May 18, 2004
    Assignee: Pfizer, Inc.
    Inventors: Robert James Crook, Alan John Pettman
  • EP4 receptor selective agonists in the treatment of osteoporosis
    Patent number: 6737437
    Abstract: This invention is directed to methods of treating conditions which present with low bone mass, particularly osteoporosis, frailty, an osteoporotic fracture, a bone defect, childhood idiopathic bone loss, alveolar bone loss, mandibular bone loss, bone fracture, osteotomy, bone loss associated with periodontitis, or prosthetic ingrowth comprising administering prostaglandin agonists which are EP4 receptor selective prostaglandin agonists. This invention is especially directed to those methods wherein the EP4 receptor selective agonist is a compound of Formula I: wherein the variables are as defined in the specification.
    Type: Grant
    Filed: December 15, 2000
    Date of Patent: May 18, 2004
    Assignee: Pfizer Inc.
    Inventors: Kimberly O. Cameron, HuaZhu Ke, Bruce A. Lefker, David D. Thompson
  • Novel macrolides
    Publication number: 20040092459
    Abstract: The invention relates to novel erythromycin analogs and azalides, particularly ones with novel C-13 substituents, and to pharmaceutically acceptable salts thereof. The compounds of this invention are antibacterial agents that may be used to treat various bacterial and protozoa infections. The invention also relates to pharmaceutical compositions containing such compounds and to methods of treating bacterial protozoa infections by administering such compounds. The invention also relates to methods of preparing such compounds and to intermediates useful in such preparation.
    Type: Application
    Filed: July 30, 2002
    Publication date: May 13, 2004
    Applicant: Pfizer Inc.
    Inventors: John Philip Dirlam, Hamish Alastair Irvine McArthur, Alan Elwood Blize
  • Method of increasing the bioavailability and tissue penetration of azithromycin
    Publication number: 20040091527
    Abstract: The bioavailability of azithromycin can be increased by co-administering azithromycin with a p-glycoprotein (p-gp) inhibitor. The azithromycin and p-gp inhibitor can be administered together in a composition or as separate components. If administered separately, they can be embodied as a kit.
    Type: Application
    Filed: October 17, 2003
    Publication date: May 13, 2004
    Applicant: Pfizer Inc
    Inventors: William J. Curatolo, George Foulds
  • Dipeptide derivatives as growth hormone secretagogues
    Patent number: RE38524
    Abstract: This invention is directed to compounds of the formula and the pharmaceutically-acceptable salts thereof, where the substituents are as defined in the Specification, which are growth hormone secretogogues and which increase the level of endogenous growth hormone. The compounds of this invention are useful for the treatment and prevention of osteoporosis and/or frailty, congestive heart failure, frailty associated with aging, obesity; accelerating bone fracture repair, attenuating protein catabolic response after a major operation, reducing cachexia and protein loss due to chronic illness, accelerating wound healing, or accelerating the recovery of burn patients or patients having undergone major surgery; improving muscle strength, mobility, maintenance of skin thickness, metabolic homeostasis or renal homeostasis.
    Type: Grant
    Filed: October 15, 2002
    Date of Patent: June 1, 2004
    Assignee: Pfizer Inc.
    Inventors: Philip Albert Carpino, David Andrew Griffith, Bruce Allen Lefker